Skip to main content

AbbVie — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

57
Companies
$2.5B
Total invested
$57.5M
Avg. check
16
Industries
Biotechnology 21Health Care 13Therapeutics 11Medical 8Pharmaceutical 4Biopharma 3+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 25–48 of 57
Alector
November 2024

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.

Biotechnology · San Francisco$50.0M Post-IPO Debt
Zag Bio
October 2025

Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases.

Biopharma · Cambridge$80.0M Series A
DISCO Pharmaceuticals
December 2025

DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.

Manufacturing · Cologne$42.3M Seed
Artios Pharma
November 2025

Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.

Biopharma · Cambridge$115.0M Series D
Syndeio Biosciences
May 2025

Syndeio Biosciences is a newly launched biotech company pioneering precision neurotherapeutics.

Biotechnology · Indianapolis$90.0M Series Unknown
ThirtyFiveBio
April 2025

ThirtyFiveBio is a biotech company developing a gut epithelial shield for patients with colitis

Biotechnology · AbingdonSeries Unknown
Starday Foods
April 2025

Starday Foods is a healthy and sustainable food products company.

Consumer · New City$8.0M Series A
Cephagenix
January 2025

Cephagenix focuses on identifying and developing new, effective migraine therapies.

Health Care · Glostrup$9.3M Seed
Light Horse Therapeutics
January 2025

Light Horse Therapeutics is a small molecule drug discovery, pioneering to target that causes disabling and life-threatening diseases.

Biotechnology · San Diego$62.0M Series A
Soufflé Therapeutics
January 2025

Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.

Biopharma · Watertown$200.0M Series A
Effector Therapeutics
January 2024

Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.

Biotechnology · San Diego$15.0M Post Ipo Equity
Accent Therapeutics
January 2024

Accent Therapeutics is a biopharmaceutical company.

Biotechnology · Lexington$75.0M Series C
Caribou Biosciences
July 2023

Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.

Biotechnology · Berkeley$125.0M Post Ipo Equity
Mozart Therapeutics
June 2023

Mozart is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases.

Biotechnology · Seattle$25.0M Series A
Quanta Therapeutics
May 2023

Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes.

Biotechnology · San Francisco$50.7M Series D
Morphic Therapeutic
May 2023

Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.

Biotechnology · Waltham$276.0M Post Ipo Equity
Capsida Biotherapeutics
February 2023

Capsida Biotherapeutics is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders.

Biotechnology · Newbury ParkCorporate Round
Jnana Therapeutics
November 2022

Jnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.

Biotechnology · Boston$107.0M Series C
Carisma Therapeutics
September 2022

Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors.

Biotechnology · Philadelphia$30.0M Series C
Nitrase Therapeutics
November 2021

Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).

Biotechnology · Jackson$7.0M Series A
Stemson Therapeutics
July 2021

Stemson Therapeutics is a pre-clinical stage cell therapy company.

Biotechnology · San Diego$15.0M Series A
Faze Medicines
December 2020

Faze Medicines is a biotechnology company.

Biotechnology · Cambridge$81.0M Series A
Caraway Therapeutics
November 2020

Rheostat Therapeutics is a bio therapeutics company.

Biotechnology · CambridgeGrant
Palleon Pharmaceuticals
September 2020

Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.

Biotechnology · Waltham$100.0M Series B

Where AbbVie invests

Biotechnology21
Health Care13
Therapeutics11
Medical8
Pharmaceutical4
Biopharma3

About AbbVie's portfolio

How many companies has AbbVie invested in?▸

AbbVie has invested in 57 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does AbbVie invest in?▸

AbbVie's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 16 different industry categories.

What is AbbVie's largest investment?▸

Among tracked funding rounds, Morphic Therapeutic received $276.0M in a Post Ipo Equity round. AbbVie's total known invested capital is $2.5B.

What is the average investment size for AbbVie?▸

AbbVie's average investment size is $57.5M across its portfolio of 57 companies.

What are AbbVie's most recent investments?▸

Recent AbbVie portfolio additions include Alector, Zag Bio, DISCO Pharmaceuticals, Artios Pharma, Syndeio Biosciences. These companies were founded in 2020 or later.

Reach the founders behind these 57 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →